Celcuity (NASDAQ:CELC) Given New $177.00 Price Target at Citizens Jmp

Celcuity (NASDAQ:CELC) had its target price increased by stock analysts at Citizens Jmp from $160.00 to $177.00 in a report released on Wednesday,Benzinga reports. The brokerage presently has a “market outperform” rating on the stock. Citizens Jmp’s price target suggests a potential upside of 87.30% from the company’s current price.

A number of other research analysts also recently weighed in on CELC. Macquarie Infrastructure set a $160.00 price target on Celcuity in a research note on Thursday, May 28th. Weiss Ratings raised Celcuity from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, June 4th. Citigroup restated an “outperform” rating on shares of Celcuity in a report on Wednesday. Stifel Nicolaus set a $150.00 target price on Celcuity in a research report on Monday, May 4th. Finally, Wells Fargo & Company decreased their target price on Celcuity from $183.00 to $166.00 and set an “overweight” rating for the company in a research report on Wednesday, June 3rd. Eleven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $154.55.

Celcuity Trading Down 14.9%

CELC opened at $94.50 on Wednesday. The firm has a 50 day simple moving average of $110.83 and a 200 day simple moving average of $111.13. Celcuity has a fifty-two week low of $13.47 and a fifty-two week high of $151.02. The company has a market cap of $4.61 billion, a price-to-earnings ratio of -23.90 and a beta of 0.16. The company has a debt-to-equity ratio of 6.04, a current ratio of 12.31 and a quick ratio of 12.31.

Celcuity (NASDAQ:CELC) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.10. On average, sell-side analysts anticipate that Celcuity will post -3.69 earnings per share for the current year.

Insider Activity

In other Celcuity news, Director Richard E. Buller sold 9,000 shares of the stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $140.46, for a total value of $1,264,140.00. Following the completion of the sale, the director directly owned 6,760 shares in the company, valued at $949,509.60. This represents a 57.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David Dalvey sold 25,000 shares of the firm’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $140.68, for a total value of $3,517,000.00. Following the sale, the director directly owned 65,000 shares in the company, valued at approximately $9,144,200. This represents a 27.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.33% of the stock is owned by corporate insiders.

Institutional Trading of Celcuity

Several hedge funds have recently bought and sold shares of the stock. EverSource Wealth Advisors LLC boosted its holdings in shares of Celcuity by 1,329.2% in the fourth quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock valued at $34,000 after buying an additional 319 shares during the period. US Bancorp DE raised its holdings in shares of Celcuity by 25.4% during the third quarter. US Bancorp DE now owns 706 shares of the company’s stock worth $35,000 after acquiring an additional 143 shares during the period. BNP Paribas Financial Markets lifted its position in Celcuity by 78.9% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock valued at $35,000 after acquiring an additional 1,167 shares in the last quarter. Parallel Advisors LLC acquired a new position in Celcuity in the 1st quarter worth $38,000. Finally, Meeder Asset Management Inc. acquired a new position in Celcuity in the 4th quarter worth $42,000. 63.33% of the stock is currently owned by institutional investors and hedge funds.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.